OFIX (Orthofix Medical) Debt-to-Revenue : 0.28 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OFIX Orthofix Medical Inc OFIX
58 GF Score
Price $9.30
GF Value $13.94
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Orthofix Medical Debt-to-Revenue?

Orthofix Medical OFIX -0.21% 58 Debt-to-Revenue is 0.28 as of Jun. 2026. GuruFocus rates OFIX with a GF Score™ of 58/100 and a GF Value™ of $13.94 (Possible Value Trap). The stock has 6 warning signs investors should review.

Debt-to-Revenue measures a company's ability to pay off its debt.

Orthofix Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.1 Mil. Orthofix Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $234.5 Mil. Orthofix Medical's annualized Revenue for the quarter that ended in Jun. 2026 was $843.7 Mil. Orthofix Medical's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 was 0.28.

Orthofix Medical Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for Orthofix Medical's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orthofix Medical Debt-to-Revenue Chart

Orthofix Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.05 0.16 0.23 0.22

Orthofix Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.25 0.20 0.33 0.28

OFIX vs MOBI, PACB, CATX: Debt-to-Revenue Comparison

For the Medical Devices subindustry, Orthofix Medical's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orthofix Medical Debt-to-Revenue vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Orthofix Medical's Debt-to-Revenue falls into.


OFIX
58GF Score
Orthofix Medical Inc OFIX
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orthofix Medical Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Orthofix Medical's Debt-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.984 + 174.451) / 822.312
=0.22

Orthofix Medical's annualized Debt-to-Revenue for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.125 + 234.494) / 843.732
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2026) Revenue data.

Frequently Asked Questions Learn more about Debt-to-Revenue →
What does a Debt-to-Revenue of 0.28 mean?
Orthofix Medical (OFIX) has a Debt-to-Revenue of 0.28 as of Jun. 2026.
Is Orthofix Medical's Debt-to-Revenue too high?
Orthofix Medical's current Debt-to-Revenue is 0.28. Overall, Orthofix Medical has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orthofix Medical's Debt-to-Revenue compare to MOBI and PACB?
Orthofix Medical's Debt-to-Revenue of 0.28 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Medical Devices & Instruments company?
A good Debt-to-Revenue depends on the Medical Devices & Instruments industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. Orthofix Medical's current Debt-to-Revenue is 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthofix Medical stock overvalued right now?
Based on GuruFocus' analysis, Orthofix Medical (OFIX) is currently considered Possible Value Trap. The stock's GF Value™ is $13.94, compared to a current price of $9.30 — trading 33.3% below its estimated fair value. The current Debt-to-Revenue is 0.28. Orthofix Medical's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For Orthofix Medical (OFIX), the current Debt-to-Revenue is 0.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orthofix Medical (OFIX) Overvalued in 2026?

Based on GuruFocus' analysis, Orthofix Medical stock appears to be undervalued. The current stock price of $9.30 is trading 33.3% below its estimated GF Value™ of $13.94. GuruFocus considers Orthofix Medical to be Possible Value Trap.

Key valuation signals for OFIX:

  • Debt-to-Revenue: 0.28
  • GF Value™: $13.94 vs. price of $9.30 (33.3% below fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the OFIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orthofix Medical Business Description

Other Exchanges OM2:Germany
Address 3451 Plano Parkway, Lewisville, TX, USA, 75056
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
58GF Score

Get the complete analysis for OFIX

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.30
Price
$13.94
GF Value